事件:2025 年12 月12 日,复宏汉霖(2696.HK)宣布,其自主研发的PD-1 抑制剂H 药(斯鲁利单抗)用于可手术胃癌围手术期治疗的上市注册申请获国家药监局受理,并被纳入优先审评程序,审评时限将大幅缩短至130 个工作日。这是全球首个针对胃癌围手术期治疗申报上市的PD-1 单抗,标志着肿瘤免疫治疗从晚期向早期治愈性治疗场景拓展的关键突破。本次事件的核心在于其“首创性”和对治疗范式的革新...
Source Link事件:2025 年12 月12 日,复宏汉霖(2696.HK)宣布,其自主研发的PD-1 抑制剂H 药(斯鲁利单抗)用于可手术胃癌围手术期治疗的上市注册申请获国家药监局受理,并被纳入优先审评程序,审评时限将大幅缩短至130 个工作日。这是全球首个针对胃癌围手术期治疗申报上市的PD-1 单抗,标志着肿瘤免疫治疗从晚期向早期治愈性治疗场景拓展的关键突破。本次事件的核心在于其“首创性”和对治疗范式的革新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.